<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05798247</url>
  </required_header>
  <id_info>
    <org_study_id>2022-CHITS-013</org_study_id>
    <nct_id>NCT05798247</nct_id>
  </id_info>
  <brief_title>Cutaneous Diphtheria in France : Observational, Retrospective Study of Patient Characteristics</brief_title>
  <acronym>OEDIPE</acronym>
  <official_title>Cutaneous Diphtheria in France : an Observational, Retrospective Study of Epidemiological, Clinical, Microbiological and Therapeutic Characteristics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre d'Epidémiologie et de Santé Publique des Armées</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Toxigenic cutaneous diphtheria is a notifiable disease that is re-emerging in the world and&#xD;
      particularly in France. A better description of the epidemiological characteristics, as well&#xD;
      as a refinement of the clinical characteristics of patients with cutaneous diphtheria, are&#xD;
      essential to better understand this pathology, which has important public health issues and&#xD;
      whose diagnosis absence can have catastrophic consequences for the patient and their&#xD;
      contacts. Microbiological data (species identification, toxigenicity or not, resistance&#xD;
      profile...) will be transmitted by the national reference center for corynebacteria of the&#xD;
      diphtheriae complex and then caregivers who have managed the corresponding patients with&#xD;
      cutaneous diphtheria will be contacted.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2023</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patients epidemiological data description</measure>
    <time_frame>3 months</time_frame>
    <description>Epidemiological data will be collected to describe the studied population (age, sex, place of birth, vaccination status...)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients clinical data description</measure>
    <time_frame>3 months</time_frame>
    <description>Clinical data will be collected to describe the studied population (history, description of lesions, disease evolution, complications...)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients microbiological data description</measure>
    <time_frame>3 months</time_frame>
    <description>Microbiological data will be collected to describe the studied population (species identification, toxigenicity, presence of a co-infection...)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients therapeutic data description</measure>
    <time_frame>3 months</time_frame>
    <description>Therapeutic data will be collected to describe the studied population (antibiotic therapy, duration of treatment, search for an eradication a posteriori...)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of antibiotic therapy duration to national recommendations issued by the High Committee of Public Health</measure>
    <time_frame>3 months</time_frame>
    <description>Duration of antibiotic therapy implemented by clinicians will be compared to national recommendations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of immunization status monitoring to national recommendations issued by the High Committee of Public Health</measure>
    <time_frame>3 months</time_frame>
    <description>Monitoring of immunization status or not will be collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of patient post infection vaccination status to national recommendations issued by the High Committee of Public Health</measure>
    <time_frame>3 months</time_frame>
    <description>Post-infection vaccination or not will be collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of patient microbiological follow-up to national recommendations issued by the High Committee of Public Health</measure>
    <time_frame>3 months</time_frame>
    <description>Microbiological follow-up with eradication research or not will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of post-infection serological sampling to national recommendations issued by the High Committee of Public Health</measure>
    <time_frame>3 months</time_frame>
    <description>Whether a post-infection serological sampling was performed or not will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of patient isolation procedures to national recommendations issued by the High Committee of Public Health</measure>
    <time_frame>3 months</time_frame>
    <description>Patient isolation or not will be collected.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">311</enrollment>
  <condition>Corynebacterium Diphtheriae Infection</condition>
  <arm_group>
    <arm_group_label>Patients with cutaneous diphteria</arm_group_label>
    <description>The study group consists of all the patients suffering from cutaneous diphtheria in metropolitan France and for which microbiological data were registered by the National Reference Center fo corynebacteria of the diphteriae complex between 2018 and 2022.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Characteristics description</intervention_name>
    <description>Caregivers who follow the patients of the study group will be contacted to collect these patients clinical and epidemiological characteristics</description>
    <arm_group_label>Patients with cutaneous diphteria</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study population corresponds to all metropolitan French patients suffering from cutaneous&#xD;
        diphtheria for which microbiological data were registered between 2018 and 2022 by the&#xD;
        National Reference Center for corynebacteria of the diphteriae complex.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Culture or PCR positive skin samples for corynebacteria diphtheria, ulcerans,&#xD;
             pseudotuberculosis, belfantii or rouxii&#xD;
&#xD;
          -  Patient living in metropolitan France&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Patient opposition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabien DUTASTA, MD</last_name>
    <role>Study Director</role>
    <affiliation>SSA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asmaa JOBIC, PhD</last_name>
    <phone>04 83 77 20 61</phone>
    <phone_ext>+33</phone_ext>
    <email>asmaa.jobic@ch-toulon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laure CHENE</last_name>
    <phone>04 83 77 20 61</phone>
    <phone_ext>+33</phone_ext>
    <email>Laure.chene4@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HIA Sainte Anne</name>
      <address>
        <city>Toulon</city>
        <state>VAR</state>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Jacques MORAND, Pr</last_name>
      <phone>04 83 16 25 71</phone>
      <phone_ext>+33</phone_ext>
      <email>dermatologie@hia-sainte-anne.ssa.msante.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-a-prevention-vaccinale/diphterie/documents/rapport-synthese/enquete-nationale-de-couverture-vaccinale-france-janvier-2011.-couverture-vaccinale-contre-la-grippe-saisonniere-dans-les-groupes-cibles-et-mesur</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/Diphtheria-cutaneous-EU-July-2015.pdf</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Bernard KA, Pacheco AL, Burdz T, Wiebe D. Increase in detection of Corynebacterium diphtheriae in Canada: 2006-2019. Can Commun Dis Rep. 2019 Nov 7;45(11):296-301. doi: 10.14745/ccdr.v45i11a04. eCollection 2019 Nov 7.</citation>
    <PMID>31755876</PMID>
  </reference>
  <reference>
    <citation>Martini H, Soetens O, Litt D, Fry NK, Detemmerman L, Wybo I, Desombere I, Efstratiou A, Pierard D. Diphtheria in Belgium: 2010-2017. J Med Microbiol. 2019 Oct;68(10):1517-1525. doi: 10.1099/jmm.0.001039.</citation>
    <PMID>31418673</PMID>
  </reference>
  <reference>
    <citation>Jaton L, Kritikos A, Bodenmann P, Greub G, Merz L. [European migrant crisis and reemergence of infections in Switzerland]. Rev Med Suisse. 2016 Apr 13;12(514):749-53. French.</citation>
    <PMID>27263151</PMID>
  </reference>
  <reference>
    <citation>Morgado-Carrasco D, Riquelme-Mc Loughlin C, Fusta-Novell X, Fernandez-Pittol MJ, Bosch J, Mascaro JM Jr. Cutaneous Diphtheria Mimicking Pyoderma Gangrenosum. JAMA Dermatol. 2018 Feb 1;154(2):227-228. doi: 10.1001/jamadermatol.2017.4786. No abstract available.</citation>
    <PMID>29282460</PMID>
  </reference>
  <reference>
    <citation>Pandit N, Yeshwanth M. Cutaneous diphtheria in a child. Int J Dermatol. 1999 Apr;38(4):298-9. doi: 10.1046/j.1365-4362.1999.00658.x. No abstract available.</citation>
    <PMID>10321948</PMID>
  </reference>
  <reference>
    <citation>Wagner KS, White JM, Lucenko I, Mercer D, Crowcroft NS, Neal S, Efstratiou A; Diphtheria Surveillance Network. Diphtheria in the postepidemic period, Europe, 2000-2009. Emerg Infect Dis. 2012 Feb;18(2):217-25. doi: 10.3201/eid1802.110987.</citation>
    <PMID>22304732</PMID>
  </reference>
  <reference>
    <citation>Gower CM, Scobie A, Fry NK, Litt DJ, Cameron JC, Chand MA, Brown CS, Collins S, White JM, Ramsay ME, Amirthalingam G. The changing epidemiology of diphtheria in the United Kingdom, 2009 to 2017. Euro Surveill. 2020 Mar;25(11):1900462. doi: 10.2807/1560-7917.ES.2020.25.11.1900462.</citation>
    <PMID>32209165</PMID>
  </reference>
  <reference>
    <citation>Koopman JS, Campbell J. The role of cutaneous diphtheria infections in a diphtheria epidemic. J Infect Dis. 1975 Mar;131(3):239-44. doi: 10.1093/infdis/131.3.239.</citation>
    <PMID>805182</PMID>
  </reference>
  <reference>
    <citation>de Benoist AC, White JM, Efstratiou A, Kelly C, Mann G, Nazareth B, Irish CJ, Kumar D, Crowcroft NS. Imported cutaneous diphtheria, United Kingdom. Emerg Infect Dis. 2004 Mar;10(3):511-3. doi: 10.3201/eid1003.030524.</citation>
    <PMID>15109425</PMID>
  </reference>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 21, 2023</study_first_submitted>
  <study_first_submitted_qc>April 3, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>April 3, 2023</last_update_submitted>
  <last_update_submitted_qc>April 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cutaneous</keyword>
  <keyword>Diphteria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

